Some subsets of pediatric sarcoma patients have very poor survival rates. We sought to determine the feasibility and efficacy of allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric sarcoma populations with <25% predicted overall survival (OS). Patients with ultrahigh-risk Ewing’s sarcoma family of tumors (ESFT), alveolar rhabdomyosarcoma, or desmoplastic small round cell tumors received EPOCH-fludarabine induction, a cyclophosphamide/fludarabine/melphalan preparative regimen, and HLA matched related peripheral blood stem cells. Thirty patients enrolled; 7 did not undergo alloHSCT because of progressive disease with diminishing performance status during induction. All 23 alloHSCT recipients experienced rapid full-donor...
The indications for hematopoietic stem cell transplantation (HSCT) in pediatric leukemias continuall...
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two...
AbstractChildren with relapsed or refractory solid tumors face dismal prognoses, and novel therapies...
Some subsets of pediatric sarcoma patients have very poor survival rates. We sought to determine the...
Background Prognosis of children with primary disseminated or metastatic relapsed sarcomas remains d...
Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, is cured with conventional ...
AbstractDuring the last 10 years, multiple studies using reduced-intensity (RI) conditioning followe...
We conducted a retrospective analysis on adult patients with advanced soft tissue sarcoma (STS) othe...
AbstractAllogeneic hematopoietic stem cell transplantation (allo-HSCT) with myeloablative conditioni...
PURPOSE: Pediatric-type sarcomas such as rhabdomyosarcoma (RMS), Ewing sarcoma (EWS), primitive neur...
BACKGROUND AND OBJECTIVESAllogeneic stem cell transplantation (SCT) offers the best chance of cure a...
INTRODUCTION AND STUDY DESIGNWe conducted a retrospective analysis of consecutive referrals of patie...
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is often recommended for patients with...
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two...
© 2013 The Cochrane Collaboration. Background: Soft tissue sarcomas (STS) are a highly heterogeneous...
The indications for hematopoietic stem cell transplantation (HSCT) in pediatric leukemias continuall...
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two...
AbstractChildren with relapsed or refractory solid tumors face dismal prognoses, and novel therapies...
Some subsets of pediatric sarcoma patients have very poor survival rates. We sought to determine the...
Background Prognosis of children with primary disseminated or metastatic relapsed sarcomas remains d...
Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, is cured with conventional ...
AbstractDuring the last 10 years, multiple studies using reduced-intensity (RI) conditioning followe...
We conducted a retrospective analysis on adult patients with advanced soft tissue sarcoma (STS) othe...
AbstractAllogeneic hematopoietic stem cell transplantation (allo-HSCT) with myeloablative conditioni...
PURPOSE: Pediatric-type sarcomas such as rhabdomyosarcoma (RMS), Ewing sarcoma (EWS), primitive neur...
BACKGROUND AND OBJECTIVESAllogeneic stem cell transplantation (SCT) offers the best chance of cure a...
INTRODUCTION AND STUDY DESIGNWe conducted a retrospective analysis of consecutive referrals of patie...
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is often recommended for patients with...
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two...
© 2013 The Cochrane Collaboration. Background: Soft tissue sarcomas (STS) are a highly heterogeneous...
The indications for hematopoietic stem cell transplantation (HSCT) in pediatric leukemias continuall...
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two...
AbstractChildren with relapsed or refractory solid tumors face dismal prognoses, and novel therapies...